Fransisca Leonard

This study identifies S100A4 as a targetable regulator of immune suppression in glioblastoma, showing its inhibition enhances immunotherapy response and survival.

This paper develops an intranasal CRISPR-based therapy targeting MAPK9 in microglia to reduce neuroinflammation after traumatic brain injury, showing reduced inflammation and no toxicity.

This study shows that combining S100A4 and TIGIT inhibition suppresses breast cancer lung metastasis by enhancing T and NK cell activity in late-stage disease.

This paper uses CRISPR to edit Rictor in myeloid cells via lipid nanoparticles, reprogramming the tumor microenvironment to enhance anti-tumor immunity in a breast cancer liver metastasis model.